Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

12 Most Undervalued Quality Stocks to Buy According to Hedge Funds

Page 1 of 11

On July 31, Nadia Lovell, UBS senior equity strategist, joined ‘The Exchange’ on CNBC to discuss why she believes this rally has staying power, and to suggest that investors stay up in quality on secular growth stories. In discussing what would give staying power to the current market levels, especially as the S&P was approaching Lovell’s firm’s upside scenario of 6700, she responded by stating that the continued pickup in the tech sector is the key factor. She emphasized a selective approach to investing, with a focus on secular growth stories within tech. She explained that tech is where the growth momentum is, with CapEx spending continuing to increase. She also highlighted the AI and electrification trends in utilities and industrials, as well as the financials sector, as other areas where investors should focus. She also noted that the IPO market is beginning to open up again.

On asking to differentiate between overheating in the market and healthy, warranted excitement, pointing to the re-emergence of meme stocks and the recent performance of crypto, Lovell responded by saying that these signs indicate an increase in investors’ risk appetite. She clarified that while there is some pickup in the meme stock trade, it is not at the same levels as a few years ago, which could present both upside and downside risk. She reiterated that investors should remain focused on where the growth is, which is in companies like the MAG7 that are delivering strong earnings growth and increasing CapEx spending.

That being said, we’re here with a list of the 12 most undervalued quality stocks to buy according to hedge funds.

A financial adviser looking over a portfolio of securities and stocks.

Our Methodology

We sifted through the Vanguard U.S. Quality Factor ETF holdings to compile a list of the top stocks that had a forward P/E ratio under 15 as of August 7. We then selected the 12 undervalued stocks that were the most popular among elite hedge funds and that analysts were bullish on. The stocks are ranked in ascending order of the number of hedge funds that have stakes in them, as of Q1 2025.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

12 Most Undervalued Quality Stocks to Buy According to Hedge Funds

12. Exelixis Inc. (NASDAQ:EXEL)

Forward P/E Ratio as of August 7: 17.06

Number of Hedge Fund Holders: 38

Exelixis Inc. (NASDAQ:EXEL) is one of the most undervalued quality stocks to buy according to hedge funds. On July 24, Exelixis announced that its partner Ipsen received approval from the European Commission/EC for CABOMETYX (cabozantinib) to treat adults with unresectable or metastatic, well-differentiated pancreatic/pNET and extra-pancreatic/epNET neuroendocrine tumors.

The approval applies to patients who have progressed after at least one prior systemic therapy, excluding somatostatin analogues. This decision allows for the marketing of CABOMETYX in all 27 member states of the European Union, as well as Norway, Liechtenstein, and Iceland. The approval follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June this year.

The EC’s approval is based on the results of the phase 3 CABINET pivotal trial. The trial evaluated CABOMETYX against a placebo in 2 groups of patients with previously treated neuroendocrine tumors: advanced pNET and advanced epNET. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival for patients treated with CABOMETYX.

Exelixis Inc. (NASDAQ:EXEL) is an oncology company that discovers, develops, and commercializes new medicines for difficult-to-treat cancers in the US.

11. Ameriprise Financial Inc. (NYSE:AMP)

Forward P/E Ratio as of August 7: 13.51

Number of Hedge Fund Holders: 40

Ameriprise Financial Inc. (NYSE:AMP) is one of the most undervalued quality stocks to buy according to hedge funds. On August 7, Ameriprise Financial announced that financial advisor Vince Abio joined S&T Financial Services, which is a financial advisory practice within the Ameriprise Financial Institutions Group/AFIG. Abio is an industry veteran with 28 years of experience and was previously with Merrill Lynch, where he managed over $120 million in client assets.

Abio chose to join Ameriprise and S&T Financial Services, which serves S&T Bank clients in Pennsylvania and Ohio. He cited the combination of Ameriprise’s financial planning capabilities and a trading platform with the scale to provide sophisticated solutions, along with S&T Bank’s community focus and clear vision for its retirement plan business as the perfect fit.

S&T Financial Services is the investment program of S&T Bank and is comprised of 15 financial advisors and 4 support staff members. The team manages a combined brokerage asset total of more than $1.4 billion. S&T Bank’s parent company, S&T Bancorp Inc. (NASDAQ:STBA), is a $9.8 billion bank holding company headquartered in Indiana, Pennsylvania.

Ameriprise Financial Inc. (NYSE:AMP) is a diversified financial services company in the US and internationally. The company operates through Advice & Wealth Management, Asset Management, and Retirement & Protection Solutions segments.

Page 1 of 11

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

<b>Cancel anytime.</b> Turn off auto-renewal via our website with just a click.

 

Buy This $3 Stock Now Before the 400% Surge Begins

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.